Iron in arterial plaque: A modifiable risk factor for atherosclerosis

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 7, 2009, Pages 718-723

  Sullivan, Jerome L ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin; Atherosclerosis; Ferritin; Haptoglobin; Heme oxygenase; Hemochromatosis; Hepcidin; Inflammation; Interleukin 6; Iron; Macrophage

Indexed keywords

ANGIOTENSIN II; DEFEROXAMINE; FERRITIN; HAPTOGLOBIN; HEME OXYGENASE 1; HEPCIDIN; INTERLEUKIN 6; IRON;

ARTERIAL WALL THICKNESS; ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CLINICAL TRIAL; DIET RESTRICTION; DISEASE MODEL; DRUG MECHANISM; FERRITIN BLOOD LEVEL; GENETIC POLYMORPHISM; HEART PROTECTION; HEMOCHROMATOSIS; HUMAN; INFLAMMATION; IRON CHELATION; IRON DEPLETION; IRON OVERLOAD; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UPREGULATION;

ANGIOTENSIN II; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ATHEROSCLEROSIS; CAROTID ARTERIES; FERRITINS; HAPTOGLOBINS; HEME OXYGENASE-1; HEMOCHROMATOSIS; HUMANS; INFLAMMATION; INTERLEUKIN-6; IRON; MACROPHAGES; POLYMORPHISM, GENETIC; RISK FACTORS;

ANIMALIA; RATTUS;

EID: 67349180293     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2008.06.005     Document Type: Review

References (91)

1. Sullivan J.L. Iron and the sex difference in heart disease risk. Lancet 1 (1981) 1293-1294
2. Sullivan J.L. The iron paradigm of ischemic heart disease. Am. Heart J. 117 (1989) 1177-1188
3. Sullivan J.L. Stored iron and ischemic heart disease. Empirical support for a new paradigm. Circulation 86 (1992) 1036-1037
4. Sullivan J.L. Stored iron and myocardial perfusion deficits. Am. Heart J. 143 (2002) 193-195
5. Sullivan J.L. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am. Heart J. 145 (2003) 190-194
6. Sullivan J.L. Stored iron and vascular reactivity. Arterioscler Thromb. Vasc. Biol. 25 (2005) 1532-1535
7. Sullivan J. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp. Biol. Med. 232 (2007) 1014-1020
8. Li W., Xu L.H., Forssel C., Sullivan J.L., and Yuan X.M. Over-expression of transferrin receptor and ferritin related to clinical symptoms and destabilization of human carotid plaques. Exp. Biol. Med. (2008) 0711-07RM
9. Hu F.B. The iron-heart hypothesis: search for the ironclad evidence. JAMA 297 (2007) 639-641
10. Marx J.J.M., Kartikasari A.E.R., and Georgiou N.A. Can iron chelators influence the progression of atherosclerosis?. Hemoglobin 32 (2008) 123-134
11. Yuan X.M., and Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann. Med. 35 (2003) 578-591
12. Franchini M., Targher G., Montagnana M., and Lippi G. Iron and thrombosis. Ann. Hematol. 87 (2008) 167-173
13. Zheng H., Cable R., Spencer B., Votto N., and Katz S.D. Iron stores and vascular function in voluntary blood donors. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1577-1583
14. Sullivan J. Is stored iron safe?. J. Lab. Clin. Med. 144 (2004) 280-284
15. Sullivan J.L., Till G.O., and Ward P.A. Iron depletion decreases lung injury after systemic complement activation. Fed. Proc. 45 (1986) 452
16. Sullivan J.L., Till G.O., Ward P.A., and Newton R.B. Nutritional iron restriction diminishes acute complement-dependent lung injury. Nutr. Res. 9 (1989) 625-634
17. Barollo M., D'Inca R., Scarpa M., Medici V., Cardin R., Fries W., Angriman I., and Sturniolo G.C. Effects of iron deprivation or chelation on DNA damage in experimental colitis. Int. J. Colorectal. Dis. 19 (2004) 461-466
18. Lee T.S., Shiao M.S., Pan C.C., and Chau L.Y. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 99 (1999) 1222-1229
19. Facchini F.S., and Saylor K.L. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann. N. Y. Acad. Sci. 967 (2002) 342-351
20. Facchini F.S., and Saylor K.L. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 52 (2003) 1204-1209
21. Facchini F.S. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology (Oxford) 42 (2003) 1-6
22. Ghio A.J., Kennedy T.P., Crissman K.M., Richards J.H., and Hatch G.E. Depletion of iron and ascorbate in rodents diminishes lung injury after silica. Exp. Lung. Res. 24 (1998) 219-232
23. Grant S.M., Wiesinger J.A., Beard J.L., and Cantorna M.T. Iron-deficient mice fail to develop autoimmune encephalomyelitis. J. Nutr. 133 (2003) 2635-2638
24. Hayashi H., Takikawa T., Nishimura N., and Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J. Hepatol. 22 (1995) 268-271
25. Kato J., Miyanishi K., Kobune M., Nakamura T., Takada K., Takimoto R., Kawano Y., Takahashi S., Takahashi M., Sato Y., Takayama T., and Niitsu Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 42 (2007) 830-836
26. Lee H.T., Chiu L.L., Lee T.S., Tsai H.L., and Chau L.Y. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J. Biomed. Sci. 10 (2003) 510-517
27. Levenson C.W., Cutler R.G., Ladenheim B., Cadet J.L., Hare J., and Mattson M.P. Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp. Neurol. 190 (2004) 506-514
28. Otogawa K., Ogawa T., Shiga R., Nakatani K., Ikeda K., Nakajima Y., and Kawada N. Attenuation of acute and chronic liver injury in rats by iron-deficient diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294 (2008) R311-R320
29. Park Y.Y., Hybertson B.M., Wright R.M., and Repine J.E. Serum ferritin increases in hemorrhaged rats that develop acute lung injury: effect of an iron-deficient diet. Inflammation 27 (2003) 257-263
30. Patt A., Horesh I.R., Berger E.M., Harken A.H., and Repine J.E. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J. Pediatr. Surg. 25 (1990) 224-227
31. Ponraj D., Makjanic J., Thong P.S., Tan B.K., and Watt F. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett. 459 (1999) 218-222
32. Sasaki K., Hashida K., Michigami Y., Bannai S., and Makino N. Restored vulnerability of cultured endothelial cells to high glucose by iron replenishment. Biochem. Biophys. Res. Commun. 289 (2001) 664-669
33. Shoham S., and Youdim M.B.H. Nutritional iron deprivation attenuates kainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration. Ann. N.Y. Acad. Sci. 1012 (2004) 94-114
34. van Jaarsveld H., and Pool G.F. Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 161 (2002) 395-402
35. Webber D.S., Lopez I., Korsak R.A., Hirota S., Acuna D., and Edmond J. Limiting iron availability confers neuroprotection from chronic mild carbon monoxide exposure in the developing auditory system of the rat. J. Neurosci. Res. 80 (2005) 620-653
36. Lee H.T., Chiu L.L., Lee T.S., Tsai H.L., and Chau L.Y. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J. Biomed. Sci. 10 (2003) 510-517
37. Minqin R., Rajendran R., Pan N., Kwong-Huat T.B., Ong W.Y., Watt F., and Halliwell B. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic. Biol. Med. 38 (2005) 1206-1211
38. Watt F., Rajendran R., Ren M.Q., Tan B.K.H., and Halliwell B. A nuclear microscopy study of trace elements Ca, Fe, Zn and Cu in atherosclerosis. Nucl. instrum. methods phys. res., B Beam interact. mater. atoms 249 (2006) 646-652
39. Smith C., Mitchinson M.J., Aruoma O.I., and Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem. J. 286 Pt 3 (1992) 901-905
40. Thong P.S., Selley M., and Watt F. Elemental changes in atherosclerotic lesions using nuclear microscopy. Cell Mol. Biol. (Noisy. -Le-Grand) 42 (1996) 103-110
41. Matthews A.J., Vercellotti G.M., Menchaca H.J., Bloch P.H., Michalek V.N., Marker P.H., Murar J., and Buchwald H. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1). J. Surg. Res. 73 (1997) 35-40
42. Minqin R., Watt F., Huat B.T., and Halliwell B. Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free. Radic. Biol. Med. 34 (2003) 746-752
43. Pang J.H., Jiang M.J., Chen Y.L., Wang F.W., Wang D.L., Chu S.H., and Chau L.Y. Increased ferritin gene expression in atherosclerotic lesions. J. Clin. Invest 97 (1996) 2204-2212
44. Porreca E., Ucchino S., Di Febbo C., Di Bartolomeo N., Angelucci D., Napolitano A.M., Mezzetti A., and Cuccurullo F. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler. Thromb. 14 (1994) 299-304
45. Dabbagh A.J., Shwaery G.T., Keaney Jr. J.F., and Frei B. Effect of iron overload and iron deficiency on atherosclerosis in the hypercholesterolemic rabbit, Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2638-2645
46. Stadler N., Lindner R.A., and Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 949-954
47. Stanley N., Stadler N., Woods A.A., Bannon P.G., and Davies M.J. Concentrations of iron correlate with the extent of protein, but not lipid, oxidation in advanced human atherosclerotic lesions. Free Radic. Biol. Med. 40 (2006) 1636-1643
48. Lapenna D., Pierdomenico S.D., Ciofani G., Ucchino S., Neri M., Giamberardino M.A., and Cuccurullo F. Association of body iron stores with low molecular weight iron and oxidant damage of human atherosclerotic plaques. Free Radic. Biol. Med. 42 (2007) 492-498
49. Yuan X.M., Brunk U.T., and Olsson A.G. Effects of iron- and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1345-1351
50. Yuan X.M., Anders W.L., Olsson A.G., and Brunk U.T. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 124 (1996) 61-73
51. Yuan X.M., and Brunk U.T. Iron and LDL-oxidation in atherogenesis. APMIS 106 (1998) 825-842
52. Yuan X.M. Apoptotic macrophage-derived foam cells of human atheromas are rich in iron and ferritin, suggesting iron-catalysed reactions to be involved in apoptosis. Free. Radic. Res. 30 (1999) 221-231
53. Yuan X.M., Li W., Baird S.K., Carlsson M., and Melefors O. Secretion of ferritin by iron-laden macrophages and influence of lipoproteins. Free. Radic. Res. 38 (2004) 1133-1142
54. Li W., Xu L.H., and Yuan X.M. Macrophage hemoglobin scavenger receptor and ferritin accumulation in human atherosclerotic lesions. Ann. N. Y. Acad. Sci 1030 (2004) 196-201
55. Li W., Hellsten A., Xu L.H., Zhuang D.M., Jansson K., Brunk U.T., and Yuan X.M. Foam cell death induced by 7[beta]-hydroxycholesterol is mediated by labile iron-driven oxidative injury: Mechanisms underlying induction of ferritin in human atheroma. Free Radic. Biol. Med. 39 (2005) 864-875
56. Li W., Ostblom M., Xu L.H., Hellsten A., Leanderson P., Liedberg B., Brunk U.T., Eaton J.W., and Yuan X.M. Cytocidal effects of atheromatous plaque components: the death zone revisited. FASEB J. 20 (2006) 2281-2290
57. Ishizaka N., Saito K., Mori I., Matsuzaki G., Ohno M., and Nagai R. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2282-2288
58. Mazzolai L., Duchosal M.A., Korber M., Bouzourene K., Aubert J.F., Hao H., Vallet V., Brunner H., Nussberger J., Gabbiani G., and Hayoz D. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension 44 (2004) 277-282
59. Asleh R., Guetta J., Kalet-Litman S., Miller-Lotan R., and Levy A.P. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ. Res. 96 (2005) 435-441
60. Moreno, P. R., Purushothaman, K. R., Purushothaman, Meerarani, Munter, P., Levy, N. S., Winterstern, A, Levy, A. P. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. [Submitted] 2008.
61. Poss K.D., and Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. PNAS 94 (1997) 10919-10924
62. Orozco L.D., Kapturczak M.H., Barajas B., Wang X., Weinstein M.M., Wong J., Deshane J., Bolisetty S., Shaposhnik Z., Shih D.M., Agarwal A., Lusis A.J., and Araujo J.A. Heme oxygenase-1 expression in macrophages plays a beneficial role in atherosclerosis. Circ. Res. 100 (2007) 1703-1711
63. Berglund L., Galbraith R.A., Emtestam L., Drummond G.S., Angelin B., and Kappas A. Heme oxygenase inhibitors transiently increase serum ferritin concentrations without altering other acute-phase reactants in man. Pharmacology 59 (1999) 51-56
64. Chen Y.H., Lin S.J., Lin M.W., Tsai H.L., Kuo S.S., Chen J.W., Charng M.J., Wu T.C., Chen L.C., Ding Y.A., Pan W.H., Jou Y.S., and Chau L.Y. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum. Genet 111 (2002) 1-8
65. Chen Y.H., Chau L.Y., Chen J.W., and Lin S.J. Serum bilirubin and ferritin levels link between heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care (2008) dc07-d2126
66. Chen J.C., Huang K.C., and Lin W.W. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell. Signal. 18 (2006) 32-39
67. Ali F., Hamdulay S.S., Kinderlerer A.R., Boyle J.J., Lidington E.A., Yamaguchi T., Soares M.P., Haskard D.O., Ralndi A.M., and Mason J.C. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J. Thromb. Haemostasis 5 (2007) 2537-2546
68. Raman S.V., Winner III M.W., Tran T., Velayutham M., Simonetti O.P., Baker P.B., Olesik J., McCarthy B., Ferketich A.K., and Zweier J.L. In vivo atherosclerotic plaque characterization using magnetic susceptibility distinguishes symptom-producing plaques. J. Am. Coll. Cardiol. Img. 1 (2008) 49-57
69. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., and Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113 (2004) 1271-1276
70. Kemna E., Pickkers P., Nemeth E., van der Hoeven H., and Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 106 (2005) 1864-1866
71. Nemeth E., and Ganz T. Regulation of iron metabolism by hepcidin. Annual. Review. of. Nutrition. 26 (2006) 323-342
72. Ganz T., and Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. Gastrointest. Liver. Physiol. 290 (2006) G199-G203
73. Kemna E., Tjalsma H., Laarakkers C., Nemeth E., Willems H., and Swinkels D. Novel urine hepcidin assay by mass spectrometry. Blood 106 (2005) 3268-3270
74. Franco R.F., Zago M.A., Trip M.D., ten Cate H., van den E.A., Prins M.H., Kastelein J.J., and Reitsma P.H. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br. J. Haematol. 102 (1998) 1172-1175
75. Sullivan J.L., and Zacharski L.R. Hereditary haemochromatosis and the hypothesis that iron depletion protects against ischemic heart disease. Eur. J Clin. Invest 31 (2001) 375-377
76. Zacharski L.R., Chow B.K., Howes P.S., Shamayeva G., Baron J.A., Dalman R.L., Malenka D.J., Ozaki C.K., and Lavori P.W. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 297 (2007) 603-610
77. Sullivan J.L., and Katz S.D. Iron reduction and cardiovascular outcomes. JAMA 297 (2007) 2075
78. Zacharski, L. R., Chow, B., Howes, P. S., Lavori, P. W., Shamayeva, G., Baron, John A., Dalman, R., Malenka, D., Ozaki, K. Effect of Reduction of Iron (Fe) Stores on Cardiovascular and Cancer Outcomes in Patients with Advanced Peripheral Arterial Disease (PAD): VA Cooperative Study #410, the Iron (Fe) and Atherosclerosis Study (FeAST). Abstract #1807. Blood 108[11], 512a-513a. 11-16-2006.
79. Zacharski L.R., Chow B.K., Howes P.S., Shamayeva G., Baron A., John R., Dalman R., Malenka D., Ozaki C., Keith, and Lavori P.W. Decreased Cancer Risk Following Reduction of Iron Stores in Patients with Peripheral Arterial Disease. Results from a randomized trial. J. Natl. Cancer Inst. (2008) djn209
80. Stevens R.G., Graubard B.I., Micozzi M.S., Neriishi K., and Blumberg B.S. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int. J. Cancer. 56 (1994) 364-369
81. Toyokuni S. Iron and carcinogenesis: from Fenton reaction to target genes. Redox. Rep. 7 (2002) 189-197
82. Yu Y., Kovacevic Z., and Richardson D.R. Tuning cell cycle regulation with an iron key. Cell Cycle 6 (2007) 1982-1994
83. Hua N.W., Stoohs R.A., and Facchini F.S. Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br. J. Nutr. 86 (2001) 515-519
84. Swaminathan S., Fonseca V.A., Alam M.G., and Shah S.V. The role of iron in diabetes and its complications. Diabetes Care (2007) dc06-d2625
85. Weinberg E.D. Iron and infection. Microbiol. Rev. 42 (1978) 45-66
86. Richardson D.R. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. N.Y. Acad. Sci. 1012 (2004) 326-341
87. Robson K.J.H., Lehmann D.J., Wimhurst V.L.C., Livesey K.J., Combrinck M., Merryweather-Clarke A.T., Warden D.R., and Smith A.D. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J. Med. Genet. 41 (2004) 261-265
88. Zecca L., Youdim M.B.H., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5 (2004) 863-873
89. Polla A.S., Polla L.L., and Polla B.S. Iron as the malignant spirit in successful ageing. Ageing Res Rev. 2 (2003) 25-37
90. Massie H.R., Aiello V.R., and Williams T.R. Inhibition of iron absorption prolongs the life span of Drosophila. Mech. Ageing Dev. 67 (1993) 227-237
91. J. Xu, M. Knutson, C. Carter, C. Leeuwenburgh, Calorie restriction attenuates age-related iron accumulation and oxidative stress in skeletal muscle and improves indices of sarcopenia. [Submitted] 2008.